Dröge LA, Perschel FH, Stütz N, et al. - Researchers analyzed patients with signs and symptoms of preeclampsia in this retrospective real-world study, to determine the clinical use of the sFlt-1 (soluble fms-like tyrosine kinase 1)/PlGF (placental growth factor) ratio alone or together with other clinical tests to predict an adverse maternal or fetal pregnancy outcome in this population. They assessed the sFlt-1/PlGF-ratio cutoff values of 38 and 85 and analyzed its integration into a multimarker model. An area under the curve of 88.7% was generated by combining all available clinical information into a multimarker model, yielding a sensitivity, specificity, positive and negative predictive value of 80.0%, 87.3%, 75.0%, and 90.2%. Inferiority of sFlt-1/PlGF-ratio alone to the full model was evident with an area under the curve of 85.7%. Significantly less accurate were blood pressure and proteinuria, with an area under the curve of 69.0%. Overall, experts concluded that in women with suspected disease, increased detection of adverse outcomes was achieved by integrating biomarker measurements with all available information in a multimarker modeling approach.